Research led by IBEC has analysed the antimicrobial activity of human histones against various bacteria, both in solution and in biofilm. The results are very promising and open the door to finding new, more effective treatments, particularly against Pseudomonas aeruginosa infections. This bacterium is mainly responsible for the development of chronic wounds and lung failure in patients with cystic fibrosis and other respiratory diseases.
IBEC will coordinate SPM4.0 and participate as a partner in ENTRY-DM, two of the projects selected in the 2023 call for PhD networks within the Marie Skłodowska-Curie Actions (MSCA). Thanks to these two projects, IBEC will add three new PhD students to its staff.
IBEC dedicates the 4th edition of its fundraising program, Faster Future, to develop novel strategies to treat infections and diseases caused by antibiotic-resistant bacteria. Specifically, the research seeks to fight … Read more
Chronic wounds are a challenge for microbiologists due to biofilms, complex structures where bacteria protect themselves from antibiotics, preventing infections from being treated effectively. A research team led by the … Read more
In a new study carried out by researchers from the Institute for Bioengineering of Catalonia (IBEC), improved so that they are more effective in much smaller doses, which opens the … Read more
Researchers at the Autonomous University of Barcelona (UAB) and Institute for Bioengineering of Catalonia (IBEC) have revealed a way to effectively deliver a mycobacterium needed for the treatment of bladder cancer in humans –using a formulation based on olive oil.The researchers have found a way to reduce the natural clumping that occurs when mycobacteria cells, which possess a high content of lipids in their walls, are introduced to the usual aqueous solutions that are used for intravesical instillation in bladder cancer patients. This clumping may interfere with the interaction of the mycobacteria-host cells and negatively influence their antitumor effects.